GlaxoSmithKline Pharmaceuticals Limited

As of June 30, 2026, GlaxoSmithKline Pharmaceuticals Limited carries a market capitalization of 415.10B, placing it among publicly traded companies globally. Its enterprise value stands at 415.10B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

GlaxoSmithKline Pharmaceuticals Limited's next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, GlaxoSmithKline Pharmaceuticals Limited has 169.41M shares outstanding.

As of June 30, 2026, GlaxoSmithKline Pharmaceuticals Limited trades at a trailing price-to-earnings ratio of 40.87.

As of June 30, 2026, GlaxoSmithKline Pharmaceuticals Limited trades at an EV/EBITDA multiple of 32.25 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 10.98 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 33.97 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 415.10B versus a market cap of 415.10B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 12.16M in revenue per employee across its workforce of 3,108.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, GlaxoSmithKline Pharmaceuticals Limited recorded 3.59B in income tax expense. That works out to an effective tax rate of 26.10, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 13.74B, leaving 10.16B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, GlaxoSmithKline Pharmaceuticals Limited's stock has declined approximately 11.78% over the past 52 weeks. The 50-day moving average sits at 2,792.31, while the 200-day moving average is 2,513.17.

Over the twelve months ended June 30, 2026, GlaxoSmithKline Pharmaceuticals Limited generated 37.80B in revenue and converted that into 10.16B in net income, yielding earnings per share of 59.95. EBITDA reached 12.87B, while operating income came in at 12.04B.

Over the twelve months ended June 30, 2026, GlaxoSmithKline Pharmaceuticals Limited posted a gross margin of 64.99, reflecting its pricing power and cost economics. The operating margin of 31.85 and net profit margin of 26.87 provide insight into operational efficiency.

GlaxoSmithKline Pharmaceuticals Limited's most recent stock split took place on September 11, 2018 with a 1:2 split ratio.